Peptide Comparison
DulaglutidevsSemaglutide
Once-weekly GLP-1 receptor agonist Fc-fusion protein (Trulicity) that reduces HbA1c by 1.5–1.9%, promotes 3–4.6 kg weight loss, and demonstrated cardiovascular event reduction in the REWIND trial — available in convenient pre-filled autoinjector with no reconstitution required
The revolutionary once-weekly GLP-1 medication that helps your body feel full faster and longer, leading to significant weight loss while also protecting your heart—FDA approved and backed by some of the largest clinical trials in obesity medicine history.
At a Glance
Quick
comparison
Dose Range
Dulaglutide
0.75–4.5 mg
Semaglutide
0.25–2.4 mg
Frequency
Dulaglutide
Once weekly
Semaglutide
Once weekly
Administration
Dulaglutide
Subcutaneous injection
Semaglutide
Subcutaneous injection
Cycle Length
Dulaglutide
Ongoing/indefinite
Semaglutide
Ongoing/indefinite
Onset Speed
Dulaglutide
Gradual (3-4 weeks)
Semaglutide
Moderate (1-2 weeks)
Evidence Level
Dulaglutide
Strong human trials (Phase 3 or FDA approved)
Semaglutide
Strong human trials (Phase 3 or FDA approved)
Efficacy
Benefit
ratings
Metabolic
Weight Management
Healing & Recovery
Weight Loss
Appetite Control
Heart Protection
Technical Data
Compound
specifications
Dulaglutide
Molecular Formula
C2646H4044N704O836S18 (complete fusion protein homodimer)
Molecular Weight
~63 kDa (~59,670 Da per chain)
Half-Life
~5 days (terminal elimination); Tmax ~48 hours; steady state in 2–4 weeks; accumulation ratio 1.56 at 1.5 mg
Bioavailability
47–65% after subcutaneous injection (dose-dependent); apparent clearance 0.142 L/h
CAS Number
923950-08-7
Semaglutide
Molecular Formula
C187H291N45O59
Molecular Weight
4113.58 g/mol
Half-Life
Approximately 7 days (168 hours)
Bioavailability
89% (subcutaneous); 0.4-1% (oral, with absorption enhancer)
CAS Number
910463-68-2
Protocols
Dosing
tiers
Dulaglutide
Semaglutide
Applications
Best
suited for
Dulaglutide
Type 2 diabetes patients seeking convenient once-weekly dosing with strong glycemic control
Dulaglutide is particularly well-suited for individuals focused on type 2 diabetes patients seeking convenient once-weekly dosing with strong glycemic control. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Patients with established cardiovascular disease or multiple CV risk factors seeking REWIND-proven cardioprotection
Dulaglutide is particularly well-suited for individuals focused on patients with established cardiovascular disease or multiple cv risk factors seeking rewind-proven cardioprotection. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Overweight or obese T2DM patients requiring both weight loss and HbA1c reduction
Dulaglutide is particularly well-suited for individuals focused on overweight or obese t2dm patients requiring both weight loss and hba1c reduction. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Pediatric patients aged 10–17 with type 2 diabetes (approved indication)
Dulaglutide is particularly well-suited for individuals focused on pediatric patients aged 10–17 with type 2 diabetes (approved indication). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Semaglutide
People with Obesity Seeking Significant Weight Loss
If your BMI is 30 or higher (or 27+ with weight-related health conditions), semaglutide is currently one of the most effective non-surgical weight loss options available. Clinical trials show average weight loss of 15% of body weight—that's 30+ pounds for someone starting at 200 pounds.
Those Who've Struggled with Diet and Exercise Alone
Semaglutide works by changing the biological signals that drive hunger and cravings. If you've tried to lose weight through willpower alone and found yourself constantly battling hunger, this medication addresses that underlying biology rather than just telling you to eat less.
People with Type 2 Diabetes Needing Better Control
Originally developed for diabetes, semaglutide excellently controls blood sugar while also promoting weight loss—addressing two major health concerns simultaneously. It can often allow people to reduce or eliminate other diabetes medications.
Individuals at High Cardiovascular Risk
The SELECT trial proved that semaglutide reduces heart attacks, strokes, and cardiovascular death by 20% in people with obesity and existing heart disease—even without diabetes. It's one of the few weight loss medications proven to improve hard cardiovascular outcomes.
Safety Profile
Side
effects
Dulaglutide
Common
- Nausea
- Diarrhea and abdominal pain
- Vomiting
- Decreased appetite
Uncommon
- Injection site reactions and fatigue
Serious
- Acute pancreatitis
- Gallbladder disease
Semaglutide
Common
- Nausea
- Constipation or Diarrhea
- Decreased Appetite
- Vomiting
Uncommon
- Gallbladder Problems
- Hair Loss (Telogen Effluvium)
Serious
- Pancreatitis
- Thyroid Tumors (Theoretical Risk)
Research Status
Safety
& evidence
Dulaglutide
Evidence Level
Strong human trials (Phase 3 or FDA approved)
FDA Status
FDA approved for this use
Safety Overview
Dulaglutide is an FDA-approved GLP-1 receptor agonist carrying a black box warning for thyroid C-cell tumor risk, based on rodent data showing increased medullary thyroid cancer (MTC) in rat models. This risk is contraindicated in patients with personal or family history of MTC or multiple endocrine neoplasia type 2. Nausea occurs in 20-40% of patients, particularly dose-dependent and most severe at initiation; gastrointestinal side effects (vomiting, diarrhea) are common. Pancreatitis has been reported in 0.1-0.2% of patients—discontinue immediately if severe abdominal pain develops. Rapid weight loss can trigger gallstone formation. Dehydration risk is significant, especially with concurrent SGLT2 inhibitors. Injection site reactions are mild but frequent.
Contraindications
- xPersonal or family history of medullary thyroid carcinoma (MTC) — black box warning based on rodent thyroid C-cell tumor data
- xMultiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- xKnown serious hypersensitivity to dulaglutide or any excipient
- xType 1 diabetes mellitus or diabetic ketoacidosis (not indicated)
Semaglutide
Evidence Level
Strong human trials (Phase 3 or FDA approved)
FDA Status
FDA approved for this use
Safety Overview
Semaglutide has been studied in over 20,000 participants across multiple large clinical trials, making it one of the most thoroughly researched weight loss medications available. The FDA approved it after rigorous review of safety data. While GI side effects are common (especially early on), serious side effects are rare. The SELECT trial showed it actually reduces cardiovascular events, adding a safety benefit beyond just weight loss.
Contraindications
- xPersonal or family history of medullary thyroid carcinoma (MTC)
- xMultiple Endocrine Neoplasia syndrome type 2 (MEN2)
- xHistory of serious allergic reaction to semaglutide
- xCurrent or recent pancreatitis
- xPregnancy or planning to become pregnant
Decision Guide
Which is
right for you?
Choose Dulaglutide if...
- Type 2 diabetes patients seeking convenient once-weekly dosing with strong glycemic control
- Patients with established cardiovascular disease or multiple CV risk factors seeking REWIND-proven cardioprotection
- Overweight or obese T2DM patients requiring both weight loss and HbA1c reduction
- Pediatric patients aged 10–17 with type 2 diabetes (approved indication)
Choose Semaglutide if...
- Significant weight loss
- Long-term weight management
- Cardiovascular risk reduction
- Blood sugar control